Lymphoma

The FDA approved pirtobrutinib as a treatment for patients with CLL/SLL who received prior BTK inhibition based on the phase 3 BRUIN-CLL-321 trial results.

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.

“We can conclude that in combination with dose-attenuated chemotherapy, [epcoritamab] may have a role in the treatment of patients with historically poor outcomes,” said Chan Cheah, MD.

An ORR of 100% was noted in the 160 mg odronextamab/CHOP cohort in untreated DLBCL.

An ORR of 91.4% was observed with zanuburtinib plus R-CHOP in patients with DLBCL.

Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.

The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.

Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

Preliminary findings from a phase 2 trial show clinical activity with MB-105 in patients with relapsed/refractory T-cell lymphoma.

The developers plan to initiate the TELLOMAK 3 trial, which will evaluate lacutamab in Sézary syndrome and mycosis fungoides, in the first half of 2026.

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.

Subcutaneous mosunetuzumab achieved consistent rates of complete responses across various high-risk marginal zone lymphoma subgroups.

There will be an unmet need for therapy in patients with aggressive lymphomas who did not benefit from therapy with bispecifics, CAR-T, chemotherapy, and targeted therapy.

The subcutaneous formulation of mosunetuzumab will require 17 cycles of therapy, without any maintenance, and can be done in outpatient settings.

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.